Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) posted its earnings results on Thursday. The company reported ($0.72) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.73 million for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.

Xenetic Biosciences Stock Performance

Shares of XBIO stock traded down $0.21 during trading on Thursday, hitting $1.66. The company had a trading volume of 21,622 shares, compared to its average volume of 40,597. The firm has a market capitalization of $3.80 million, a P/E ratio of -1.43 and a beta of 2.36. The stock’s 50-day moving average price is $2.53 and its 200 day moving average price is $2.82. Xenetic Biosciences has a one year low of $1.58 and a one year high of $4.94.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.